Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report highlights a stable growth in social consumption, with a year-on-year increase of 4.7% in the first four months of 2025, and a 5.1% increase in April [4] - The report emphasizes the strong performance of optional consumption categories, particularly gold and jewelry, which saw a year-on-year increase of 25.3% in April [5] - Online retail channels showed robust growth, with a total online retail sales of 47,419 billion in the first four months of 2025, marking a 7.7% increase [6] Summary by Sections Industry Overview - The total retail sales for the first four months of 2025 reached 161,845 billion, with April sales at 37,174 billion, reflecting a 5.1% increase [4] - The report indicates a positive outlook for social consumption growth driven by effective policy measures [4] Consumption Trends - Essential consumption categories such as grain and oil saw significant growth, with year-on-year increases of 14.0% for grain and oil products [5] - The report identifies a divergence in growth rates among different consumption categories, with home appliances showing a strong performance due to government subsidies [5] Online vs Offline Retail - Online retail sales accounted for 24.3% of total retail sales, with physical goods online retail sales increasing by 5.8% [6] - Offline retail channels, including supermarkets and convenience stores, also showed a marginal recovery, with supermarkets growing by 5.2% year-on-year [6] Investment Recommendations - The report suggests focusing on high-quality companies in the "emotional consumption" theme, particularly in four key areas: gold and jewelry, offline retail, cosmetics, and medical aesthetics [7] - Specific companies recommended include Lao Pu Gold, Yonghui Supermarket, and Aimeike, among others [7]

对玻尿酸（透明质酸）、重组胶原蛋白两种流行医美原料的比较，引发了医美巨头华熙生物(688363)对 多家券商研报的公开"声讨"。 深夜发文"声讨" 5月17日晚23时许，华熙生物官方微信号发文《概念总在重演，科技永远向前》，将矛头指向多家券商 研报，相关研报提出胶原蛋白在皮肤修复、抗衰老和副作用等方面强于玻尿酸。 华熙生物在微信文章中表示，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被 看似幸运地选中了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业的研报中，出现了大量 直接针对中国透明质酸产业的所谓"对比研究"。 包括华泰证券、安信证券等多家券商研报被华熙生物节选发在了上述文章中。华熙生物文章称，这些误 导性"结论"伴随着随后兴起的"玻尿酸过时论"被媒体和自媒体红人广泛传播，形成了资本市场与消费市 场的舆论共振，伤害了经几代人努力的、一个中国优势产业的市场转化基础。 华熙生物表示，透明质酸这一成分及相关产业在近几年资本市场的概念切换中遭遇了谎言与践踏，被描 述为"过时""不如某物质安全""不如某物质更具生物活性""不如某物质具备市场价值"……这些抹黑与受 操控的自媒体及网络上的虚 ...

悄悄地、悄悄地，一年声量比一年小的618大促已经来了好几天。 今年你参加了吗？ 5月13日晚上8点，李佳琦在直播间大喊"所有女生快冲"，正式拉开了今年618的帷幕。 从厂商们的赚钱密码跌落至无人在意，今年的618你几乎看不到任何大卖的新闻。另一边，"优惠力度还没有38大""越凑越没劲儿"的说法却遍地开花。 甚至有一个品牌，预售当晚还被叫做"新晋国货顶流"，在李佳琦直播间内，预售一小时后该品牌销量就升至第三，还登上了天猫美妆预售TOP20，前有娇 韵诗、OLAY，后有娇兰、资生堂。 却没想到，一夜之间就变成了"618最下头商家"。 "618最下头商家"，把女金主踢下牌桌 直播间"眼看他起高楼，眼看他楼塌了"的故事层出不穷，却没想今年的来得如此之快。 从"新晋国货顶流"跌落至"618最下头商家"的国货美妆品牌叫做同频，2024年9月才成立，而在2个月后，就拿到了天猫双11全周期的快消新商第一，旗下 大单品在去年的李佳琦双11大促中，同频次抛精华开卖即售罄，胶原面膜在修护品类中仅次于欧莱雅安瓶和理肤泉。 图源：小红书@慧主编来了 到了今年618大促，次抛精华和面膜在李佳琦直播间同样开卖后就"3秒售罄"，分别预售10 ...

Report Summary 1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The consumer market has shown significant structural differentiation and opportunities. New consumption sectors such as trendy toys, pet economy, and AI+ have emerged, while traditional sectors like liquor have faced challenges due to economic pressure [21]. - Different stages of the consumer market are characterized by distinct investment styles. For example, in the core - asset - dominated stage, low - turnover and growth - style consumer funds outperformed; in the market - oscillation stage, value - style funds with flexible and diversified holdings had an edge [36][57]. - The performance of consumer funds is closely related to macro - economic conditions, policy support, and market sentiment. In weak market environments, dividend - value style funds with strong stock - picking abilities tend to perform better [70]. 3. Summary by Relevant Catalogs 3.1 Consumption Market Historical Review - **Core Asset Dominated (20190101 - 20210210)**: The market trended upward. The relaxation of domestic policies, inflow of foreign capital, and economic recovery promoted investment opportunities in the consumer sector, especially in the liquor industry. The CSI Liquor Index rose over 350% [13]. - **Repeated Oscillation (20210218 - 20230116)**: Factors such as the pandemic, macro - economic pressure, and geopolitical issues led to market oscillations. There were structural rotation opportunities in high - end consumption, pig farming, and other sectors [13]. - **Oscillation Decline (20230117 - 20240202)**: The market first rose and then declined. The weak economic recovery and low consumer confidence led to a decline in the consumer industry, especially in the real - estate post - cycle and food and beverage industries. The CSI Liquor Index fell nearly 38% [21]. - **New Consumption Dominated (20240205 - 20250415)**: The consumer market showed structural differentiation. New consumption sectors such as trendy toys, pet economy, and AI+ performed well, while the liquor industry still faced pressure. The CSI Liquor Index fell 3.8%, and the Xinhua SHS Emerging Consumption Index rose 53% [21]. 3.2 Consumption Fund Holdings - **Stock - holding Proportion**: The proportion of liquor holdings in consumer funds reached a peak in 2023 (about 41%) and then declined to about 30% in 2024. The proportion of new - consumption holdings increased from about 10% in 2019 to 25.7% at the end of 2024 [29]. - **Stock - holding Contribution**: Liquor has been the main source of continuous contribution to consumer funds since 2019. New - consumption stocks have made significant contributions since 2024, with companies like Pop Mart leading the way [29]. - **HK Stock Holdings**: Consumer funds' holdings of HK stocks are mainly concentrated in the new - consumption field. The proportion of HK - stock holdings increased in 2020 and 2024, mainly due to the layout of new consumption [33]. 3.3 Fund Return Sources and Portraits - **Stage One (20190101 - 20210210)**: High - growth consumer funds with low turnover and high retention of heavy - position stocks outperformed. The expansion of liquor channels and the upgrade of price ranges drove the growth of the consumer market [36]. - **Stage Two (20210218 - 20230116)**: Funds with a balanced and slightly value - oriented style and flexible and diversified holdings performed better. The moderate increase in CPI and the decline in PPI benefited the consumer industry, and value - type consumer stocks showed high defensive properties [57]. - **Stage Three (20230117 - 20240202)**: Funds with a deep - value style and strong alpha capabilities outperformed. In a weak market environment, low - volatility, high - dividend stocks became a safe haven for funds [70]. - **Stage Four (20240205 - 20250411)**: The elasticity and stock - picking ability of consumer funds in the new - consumption field became the key to returns. Traditional companies' second - growth curves and the growth of new consumption drove the performance of consumer funds [84]. 3.4 Consumption ETF Funds - **A股 - related ETFs**: There are ETF funds corresponding to 5 A - share consumer comprehensive indices, with the largest number (3) and total scale (27 billion yuan) corresponding to the CSI Consumption 50 Index [95]. - **港股 - related ETFs**: There are ETF funds corresponding to 5 HK - stock consumer comprehensive indices, with the largest number (4) corresponding to the CSI Hong Kong Stock Connect Consumption Index and the largest total scale (33.5 billion yuan) corresponding to the Hang Seng Consumption Index [95].

Core Viewpoint - The article discusses the backlash from Huaxi Biological against the notion that hyaluronic acid is "outdated," attributing this perspective to a misleading narrative constructed by "restless capital" and certain brokerage reports [1][4]. Group 1: Market Dynamics - Huaxi Biological published an article refuting the "outdated hyaluronic acid" claim, stating that this narrative undermines the efforts of Chinese scientists and the industry [1]. - The rise of the "outdated hyaluronic acid" theory is seen as a tactic to divert attention from the necessary evolution of the industry, pushing capital towards new themes [4]. Group 2: Brokerage Reports - Multiple brokerage reports, including those from Western Securities, were specifically named by Huaxi Biological for spreading misleading comparisons that favor a collagen company over the hyaluronic acid industry [6]. - Huaxi Biological emphasized that these misleading conclusions have been widely disseminated by media and influencers, creating a negative perception that harms the market foundation of a competitive Chinese industry [6]. Group 3: Financial Performance - Huaxi Biological's stock price peaked at 309.43 CNY per share in July 2021 but has since been on a downward trend, closing at 50.60 CNY on May 19, 2023, reflecting a long-term decline [9][12]. - The company reported a significant drop in revenue from its skin science innovation business, which accounted for nearly half of its revenue, with a year-on-year decline of 31.62% [11]. Group 4: Market Position - Huaxi Biological's market capitalization has decreased from over 1,400 billion CNY at its peak to approximately 244 billion CNY currently [12]. - In contrast, competitors like Juzhi Biological and Jinbo Biological have seen their market values rise significantly, with Juzhi Biological nearing 900 billion HKD and Jinbo Biological's stock price doubling recently [15].

Macro Commentary - The US economy shows signs of slowing down, with significant declines in retail and manufacturing output due to tariff impacts, particularly affecting durable goods like automobiles and electronics [2] - Despite the slowdown, unemployment claims remain stable, indicating that the service sector is less affected, and employment in this sector remains robust [2] - Inflation is expected to rebound temporarily from May to August, with the Federal Reserve likely to maintain interest rates until September, when a potential rate cut may occur [2] Industry Commentary - The Chinese pharmaceutical sector is experiencing a strong trend in innovative drug exports, with several significant business development transactions occurring despite recent tariff tensions [5][6] - The MSCI China Healthcare Index has risen by 14.9% since early 2025, although it has underperformed compared to the broader MSCI China Index [5] - The US innovative drug prices are unlikely to decrease in the short term due to recent executive orders, but long-term pressures on healthcare spending are anticipated [7] Company Initiation - The report covers Angelalign Technology (6699 HK), a leading provider of invisible orthodontic solutions in China, which has maintained a market share of 42% in the domestic market [9][10] - The company is expected to achieve a revenue compound annual growth rate (CAGR) of 23.8% from 2019 to 2024, with a projected CAGR of 18.0% from 2024 to 2027 [9] - Angelalign is expanding internationally, with a goal to cover over 50 countries and achieve significant revenue growth from overseas markets, which is expected to account for 30% of total revenue by 2024 [11][12]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [2] Core Insights - The retail industry is experiencing a significant shift with the 618 e-commerce promotion, characterized by extended activity periods and simplified consumer engagement strategies [27][28] - Domestic beauty brands are showing strong performance, with notable sales figures during the 618 promotion, indicating a trend of rising domestic products [5][32] Summary by Sections Retail Market Review - The retail industry index rose by 1.72% during the week of May 12 to May 16, outperforming the Shanghai Composite Index by 0.96 percentage points [7][16] - The internet e-commerce sector saw the highest growth, with a weekly increase of 5.81%, while the brand cosmetics sector led the year-to-date performance with a 20.30% increase [19][22] 618 Promotion Insights - The 618 e-commerce promotion has begun, with platforms like Taobao, Douyin, and JD extending their promotional periods and simplifying discount mechanisms to enhance consumer experience [27][28] - Sales performance during the promotion has been strong, with Li Jiaqi's live stream achieving a GMV of 25-35 billion yuan on the first day, showcasing the rising dominance of domestic beauty brands [5][32] Investment Recommendations - Focus on high-quality companies in the emotional consumption theme, particularly in sectors like gold jewelry, offline retail, cosmetics, and medical aesthetics [8][35] - Recommended companies include Lao Pu Gold, Chao Hong Ji, Mao Ge Ping, Peiliya, Juzi Biology, and Shangmei Shares, which are expected to benefit from current market trends [38]

Core Insights - Synthetic biology is at a pivotal growth point in China, attracting significant attention from global investors due to its unique innovation potential and broad application prospects [1] - The Chinese synthetic biology market comprises 116 listed companies, including technology platform providers, CXO companies offering biosynthesis solutions, and chemical and pharmaceutical companies seeking transformation [1] - The industry showcases a mix of established players with decades of experience and newly founded companies, highlighting the vast development potential and imagination space behind synthetic biology [1] Industry Overview - Enabling technology companies in synthetic biology are experiencing rapid growth, leveraging cutting-edge technologies such as gene editing, gene synthesis, gene sequencing, big data, and machine learning [1] - Current enabling technologies are still in their early stages, with high technical barriers, leading companies to pursue collaborations with universities, research institutions, and other enterprises to advance R&D [1] Leading Companies - BGI Genomics and Berry Genomics are recognized as leaders among enabling technology companies in China's synthetic biology sector [2] - BGI Genomics focuses on gene sequencing instruments, laboratory automation, and new business areas, enhancing its global influence in precision medicine and health [3] - Berry Genomics, a leader in gene sequencing, offers services in reproductive health, genetic disease detection, and tumor detection, supported by proprietary technologies like PCR-free methods [6] Platform Companies - Synthetic biology platform companies primarily provide services related to process improvement and enzyme engineering, with few achieving the functionality of cell factories [9] - Kingfisher Biotech is a prominent global gene supplier, evolving into a leading provider of research and production services with a strong reputation in life sciences [11] - Yikole Biotech specializes in synthetic biology technology, focusing on biomanufacturing and possessing a vast library of over 20,000 enzymes [13][16] Emerging Trends - The Chinese synthetic biology sector is witnessing a surge in investment opportunities driven by policy guidance and market demand, with companies increasing their focus on technological innovation and R&D [22] - Key application areas include biopharmaceutical raw materials, bio-based materials, and the development of cell and gene therapy drugs, supported by integrated R&D and production capabilities [16][20]

Investment Rating - The report maintains an "Overweight" rating for the retail industry [1] Core Insights - The 2025 618 shopping festival has been advanced, with discounts shifting from "spend 300 get 50 off" to direct reductions, enhancing consumer shopping experience and reducing the need for bundling [4][9] - The performance of domestic beauty brands has been strong, with notable sales figures during the initial live stream of the festival, achieving a GMV of 25-35 billion yuan [4][11] - The report recommends focusing on brands like Zhenjia, Ru Yuchen, and others that are expected to perform well during the 618 festival [4][13] Industry Trends - The 2025 618 shopping festival started on May 13, 2025, approximately 7 to 10 days earlier than in 2024, extending the event duration to 35-40 days, marking the longest period in history [4][9] - Major platforms such as Taotian, JD, Pinduoduo, and Douyin launched their promotions simultaneously, indicating increased competition [4][9] - Domestic beauty brands like Perleya and Kefu Mei have shown significant growth, with Kefu Mei rising from 6th to 3rd place in the beauty sales rankings [4][13] Market Performance - From May 12 to May 16, 2025, the Shenwan retail index increased by 1.72%, while the beauty care sector rose by 3.08% [14] - Year-to-date performance shows the Shenwan retail index up by 8.93%, outperforming the broader market indices [14][21] Company Valuation - The report includes a valuation table for various companies, highlighting their market capitalization and projected earnings [16][18] - Companies such as Perleya and Juzhi Biotech are rated as "Buy," indicating strong expected performance [17][18]

Investment Rating - The report maintains an "Overweight" rating for the retail industry [1] Core Insights - The 2025 618 shopping festival has been advanced, with discounts shifting from "spend 300 get 50 off" to direct reductions, enhancing consumer shopping experience and reducing the need for bundling [4][9] - The performance of domestic beauty brands has been strong, with notable sales figures during the initial live stream of the festival, achieving a GMV of 25-35 billion yuan [4][11] - The report highlights the rapid growth of brands like Zhenjia in the home cleaning sector and recommends focusing on companies like Juzi Biological, Shangmei Shares, and others during the 618 festival [4][13] Summary by Sections Industry Outlook - The 2025 618 shopping festival started on May 13, 2025, approximately 7 to 10 days earlier than in 2024, extending the event duration to 35-40 days, marking the longest period in history [4][9] - Major platforms such as Taotian, JD, Pinduoduo, and Douyin launched their promotions simultaneously, indicating increased competition [4][9] Market Performance - From May 12 to May 16, 2025, the Shenwan retail index increased by 1.72%, while the beauty care sector rose by 3.08% [14] - Year-to-date performance shows the Shenwan retail index up by 8.93%, outperforming other indices like the Shanghai Composite [14][21] Company Valuation - The report includes a valuation table for various companies, with several brands like Perleya and Juzi Biological receiving "Buy" ratings based on their projected earnings growth [17][18]